Genmab A/S (GMAB) Q2 2023 Earnings Conference Call August 3, 2023 12:00 PM ET
Company Participants
Jan van de Winkel - Co-Founder, President & CEO
Anthony Pagano - EVP & CFO
Judith Klimovsky - Chief Development Officer
Anthony Mancini - COO
Conference Call Participants
Vikram Purohit - Morgan Stanley
Peter Verdult - Citigroup Inc.
Sachin Jain - Bank of America
Michael Schmidt - Guggenheim
Asthika Goonewardene - Truist Securities
Emily Field - Barclays
Yaron Werber - TD Cowen
Xian Deng - UBS
Peter Welford - Jefferies
Matthew Phipps - William Blair
Rajan Sharma - Goldman Sachs
Faisal Khurshid - Leerink Partners
Operator
Hello, and welcome to Genmab's Second Quarter 2023 Financial Results Conference Call. As a reminder, this conference call is being recorded.
During this telephone conference, you may be presented with forward-looking statements that include words such as believes, anticipates, plans, or expects. Actual results may differ materially, for example, as a result of delays or and successful development projects. Genmab is not under any obligation to update statements regarding the future nor to confirm such statements in relation to actual results unless this is required by law.
Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy.
I would now like to hand the conference over to your first speaker today, Jan van de Winkel. Please go ahead.
Jan van de Winkel
Hello, and welcome to Genmab's conference call to discuss our financial results for the period ending June 30, 2023. With me today to present these results is our CFO, Anthony Pagano. For the Q&A, we will be joined by our Chief Development Officer, Judith Klimovsky; and our Chief Operating Officer, Anthony Mancini.
As already said, we will be making forward-looking statements, so please keep that in mind as we go through this call. During today's presentation, we will reference products being developed under some of our strategic collaborations. And this slide acknowledges those relationships. In May, EPKINLY became the first T-cell engaging bispecific antibody approved for use in the U.S. for third line plus diffuse large B-cell lymphoma. With this approval, we achieved an important milestone, both for Genmab and most importantly, for patients with third line plus diffuse large B-cell lymphoma who are in need of an innovative treatment option administered subcutaneously.